AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00446134
Drug: Taribavirin
RxNorm normalized name: Taribavirin
DrugBank: Taribavirin (DB06408)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral (200 mg) Tablet: 25mg/kg/day BID, patients will be treated for a total of 48 weeks. in addition, all patients will receive peginterferon alfa-2b (PEG-Intron) by weekly subcutaneous injection. Patients who complete treatment with study drug or discontinue treatment prematurely will enter a 24-week follow-up period.
Trial: NCT00446134
Drug: Taribavirin
RxNorm normalized name: Taribavirin
DrugBank: Taribavirin (DB06408)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral (200mg)Tablet: 30mg/kg/day BID, patients will be treated for a total of 48 weeks. in addition, all patients will receive peginterferon alfa-2b (PEG-Intron) by weekly subcutaneous injection. Patients who complete treatment with study drug or discontinue treatment prematurely will enter a 24-week follow-up period.
Trial: NCT00446134
Drug: Ribavirin
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral (200mg)Tablet: 800 mg/day, 1000 mg/day, 1200 mg/day, or 1400 mg/day BID, patients will be treated for a total of 48 weeks. in addition, all patients will receive peginterferon alfa-2b (PEG-Intron) by weekly subcutaneous injection. Patients who complete treatment with study drug or discontinue treatment prematurely will enter a 24-week follow-up period.
Trial: NCT02792088
Drug: Besifovir 150mg
RxNorm normalized name: Besifovir
DrugBank: Besifovir (DB15671)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Besifovir 150 mg q.d. + Placebo of Tenofovir Disoproxil Fumarate 300 mg q.d. + L-carnitine (L-Carn Tab. 330 mg) 660 mg q.d.
Trial: NCT02792088
Drug: Tenofovir 300mg
RxNorm normalized name: EMTRICITABINE 200MG/TENOFOVIR 300MG TAB
DrugBank: Tenofovir (DB14126)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Placebo of Besifovir 150 mg q.d. + Tenofovir Disoproxil Fumarate 300 mg q.d. + Placebo of L-carnitine (L-Carn Tab. 330 mg) 660 mg q.d.
Trial: NCT02149199
Drug: terbutaline 'as needed' + placebo budesonide bid
DrugBank: Terbutaline (DB00871)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Terbutaline 0.4 mg powder for inhalation 'as needed' plus placebo Pulmicort (budesonide) 200 μg powder for inhalation, 1 inhalation twice daily (morning and evening), 52-week treatment
Trial: NCT01246908
Drug: CX157 (TriRima)
RxNorm normalized name: CX157
DrugBank: CX157 (DB05205)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One tablet administered twice per day (total daily dose of 250 mg) for six weeks.
Trial: NCT02173262
Drug: G-CSF
RxNorm normalized name: G-CSF
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02173262
Drug: Ciprofloxacin
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02683746
Drug: Lyophilized albiglutide DCC pen injector
RxNorm normalized name: albiglutide Pen Injector
DrugBank: Albiglutide (DB09043)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A fixed-dose, fully disposable pen injector system with a prefilled dual chamber glass cartridge (DCC) containing lyophilized albiglutide (30mg or 50mg) delivering an injection volume of 0.5mL.
Trial: NCT02683746
Drug: Lyophilized albiglutide DCC pen injector matching placebo
RxNorm normalized name: albiglutide Pen Injector
DrugBank: Albiglutide (DB09043)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A fixed-dose, fully disposable pen injector system with a prefilled DCC containing matching placebo delivering an injection volume of 0.5mL
Trial: NCT02683746
Drug: Albiglutide liquid auto-injector
RxNorm normalized name: albiglutide Pen Injector
DrugBank: Albiglutide (DB09043)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A fixed-dose, single use, disposable auto-injector containing albiglutide liquid (30mg or 50mg) in a prefilled glass syringe. The auto-injector delivers the albiglutide liquid in an injection volume of 0.6 mL for the 30mg dose and 1.0 mL for the 50mg dose.
Trial: NCT02683746
Drug: Albiglutide liquid auto-injector matching placebo
RxNorm normalized name: albiglutide Pen Injector
DrugBank: Albiglutide (DB09043)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A fixed-dose, single use, disposable auto-injector containing matching placebo in a prefilled glass syringe. The auto-injector delivers the matching placebo in an injection volume of 0.6 mL for the 30mg dose and 1.0 mL for the 50mg dose.
Trial: NCT01191216
Drug: 1-methyl-d-tryptophan
RxNorm normalized name: 1-methyl-D-tryptophan
DrugBank: Indoximod (DB12827)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01191216
Drug: docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00401362
Drug: SC Methylnaltrexone
DrugBank: Naltrexone (DB00704)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dose 1
Trial: NCT00401362
Drug: SC Methylnaltrexone
DrugBank: Naltrexone (DB00704)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dose 2
Trial: NCT02047318
Drug: LUM001 (Maralixibat)
RxNorm normalized name: Maralixibat
DrugBank: Maralixibat (DB16226)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosing of LUM001 also known as Maralixibat (MRX) with the objective of achieving optimal control of pruritus at a dose level that is tolerated by the participant and up to a maximum daily dose of 560 micrograms per kilogram (mcg/kg).
Trial: NCT00924781
Drug: MK2578 1 mcg for every 350 U of Epogen (epoetin alfa) received per week at Baseline
RxNorm normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MK2578 was to be administered IV. Participants in Cohort 2 were to receive 1 mcg of MK2578 for every 350 U of Epogen (epoetin alfa) received per week at Baseline. Participants were to be randomized to QW or QM dosing schedules within each cohort.
Trial: NCT00924781
Drug: MK2578 1 mcg for every 200 U of Epogen (epoetin alfa) received per week at Baseline
RxNorm normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MK2578 was to be administered IV. Participants in Cohort 3 were to receive 1 mcg of MK2578 for every 200 U of Epogen (epoetin alfa) received per week at Baseline. Participants were to be randomized to QW or QM dosing schedules within each cohort.
Trial: NCT00689442
Drug: JTT-705 600 mg and atorvastatin 20 mg
RxNorm normalized name: atorvastatin and amlodipine
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: * JTT-705 300 mg tablets, 600 mg dose, oral, once daily, immediately following breakfast and/or assessment~* Atorvastatin 20 mg tablets, 20 mg dose, oral, once daily, immediately following breakfast and/or assessments
Trial: NCT00689442
Drug: Placebo and atorvastatin 20 mg
RxNorm normalized name: atorvastatin 20 MG
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: * Placebo tablet, 2 tablets, oral, once daily, immediately following breakfast and/or assessments~* Atorvastatin 20 mg tablets, one tablet, oral, once daily, immediately following breakfast and/or assessments
Trial: NCT01097083
Drug: Coriolus Versicolor
RxNorm normalized name: TRAMETES VERSICOLOR
DrugBank: Trametes versicolor fruiting body (DB14287)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01073371
Drug: Prilocaine
RxNorm normalized name: Prilocaine
DrugBank: Prilocaine (DB00750)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1.8mL infiltration of liposome-encapsulated 3% prilocaine, 3% plain prilocaine or 3% prilocaine with 0,03IU/mL felypressin in the buccal sulcus of the maxillary right canine
Trial: NCT02208778
Drug: Duloxetine
RxNorm normalized name: Duloxetine
DrugBank: Duloxetine (DB00476)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 54 participants will be allocated for duloxetine treatment
Trial: NCT00865423
Drug: Gabapentin 800 mg Tablets, single dose
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A: Experimental Subjects received Purepac formulated products under fasting conditions
Trial: NCT00100334
Drug: PPI-1019 (APAN)
RxNorm normalized name: PPI-1019
DrugBank: PPI-1019 (DB05832)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01566695
Drug: Oral Azacitidine
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 300 mg daily, days 1 to 21 of each 28-day treatment cycle
Trial: NCT01104532
Drug: sitagliptin
RxNorm normalized name: Sitagliptin
DrugBank: Sitagliptin (DB01261)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: oral tablet
Trial: NCT00370045
Drug: Bivalirudin with and without eptifibatide
DrugBank: Bivalirudin (DB00006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00390026
Drug: Bevacizumab (Avastin)
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00390026
Drug: Verteporfin photodynamic therapy (PDT)
RxNorm normalized name: Verteporfin
DrugBank: Verteporfin (DB00460)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02815280
Drug: Vehicle Foam
RxNorm normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
DrugBank: Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle (DB10786)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle foam applied topically once daily for 12 weeks
Trial: NCT00040846
Drug: fludarabine phosphate
RxNorm normalized name: Fludarabine Phosphate
DrugBank: Fludarabine (DB01073)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT02174549
Drug: Tirapazamine
RxNorm normalized name: Tirapazamine
DrugBank: Tirapazamine (DB04858)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-arterial injection into the tumor feeding artery
Trial: NCT00040846
Drug: mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT00040846
Drug: cyclosporine
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV or PO
Trial: NCT03594175
Drug: CUSA-081
RxNorm normalized name: Cusatuzumab
DrugBank: Cusatuzumab (DB15100)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received 1 or 2 doses of CUSA-081 0.7 mg/2 mL directly into the catheter lumen
Trial: NCT03594175
Drug: Alteplase
RxNorm normalized name: Alteplase
DrugBank: Alteplase (DB00009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants received 1 or 2 doses of alteplase, 2 mg/2 mL, directly into the catheter lumen
Trial: NCT03513445
Drug: Morphine
RxNorm normalized name: Morphine
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Morphine, epinephrine, and ropivacaine cocktail will be administered peri-incisionally during lumbar spine surgery.
Trial: NCT03513445
Drug: naropin
RxNorm normalized name: Naropin
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Morphine, epinephrine, and ropivacaine cocktail will be administered peri-incisionally during lumbar spine surgery.
Trial: NCT01230177
Drug: etanercept (genetical recombination)
RxNorm normalized name: Etanercept
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 10 to 25 mg of etanercept (genetical recombination) reconstituted in 1 mL of water for injection (JP) administered twice weekly as a subcutaneous injection or 25 to 50 mg of etanercept (genetical recombination) administered once weekly as a subcutaneous injection, are usually the recommended dose for adults.
Trial: NCT01534182
Drug: Fingolimod
RxNorm normalized name: Fingolimod
DrugBank: Fingolimod (DB08868)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 0.5 mg orally once a day
Trial: NCT01534182
Drug: Interferon beta - 1a (IFN)
RxNorm normalized name: interferon beta-1a
DrugBank: Interferon beta-1a (DB00060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 44 mcg subcutaneously three times a week
Trial: NCT01534182
Drug: Glatiramer acetate (GA)
RxNorm normalized name: Glatiramer
DrugBank: Glatiramer (DB05259)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg subcutaneously once a day
Trial: NCT01479283
Drug: 24-Hour Prophylactic Cefazolin* Antibiotic Regimen
DrugBank: Cefazolin (DB01327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pre-Operative Antibiotic Regimen: Patients will receive 2g (or a weight-based dose based on 100mg/kg/day with a maximum single dose of 2g if \< 18 years old) of IV cefazolin within 60 minutes prior to the procedure. No other pre-operative antibiotics will be administered.~Intra-Operative Antibiotic Regimen: Patients will receive 2g (or a weight-based dose based on 100mg/kg/day with a maximum single dose of 2g if \< 18 years old) of IV cefazolin every 3-4 hours. No other intra-operative antibiotics will be administered.~Post-Operative Antibiotic Regimen: Patients will receive 2g (or a weight-based dose based on 100mg/kg/day with a maximum single dose of 2g if \< 18 years old) of IV cefazolin every 8 hours for 24 hours followed by IV saline for 4 days. No other post-operative antibiotics will be administered.
Trial: NCT01479283
Drug: 5-Days Prophylactic Cefazolin* Antibiotic Regimen
DrugBank: Cefazolin (DB01327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pre-Operative Antibiotic Regimen: Patients will receive 2g (or a weight-based dose based on 100mg/kg/day with a maximum single dose of 2g if \< 18 years old) of IV cefazolin within 60 minutes prior to the procedure. No other pre-operative antibiotics will be administered.~Intra-Operative Antibiotic Regimen: Patients will receive 2g (or a weight-based dose based on 100mg/kg/day with a maximum single dose of 2g if \< 18 years old) of IV cefazolin every 3-4 hours. No other intra-operative antibiotics will be administered.~Post-Operative Antibiotic Regimen: Patients will receive 2g (or a weight-based dose based on 100mg/kg/day with a maximum single dose of 2g if \< 18 years old) of IV cefazolin every 8 hours for 5 days. No other post-operative antibiotics will be administered.
Trial: NCT03313661
Drug: Cabergoline
RxNorm normalized name: Cabergoline
DrugBank: Cabergoline (DB00248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: cabergoline 0.5 mg twice weekly within 2 hrs of awakening plus gliclazide
Trial: NCT03313661
Drug: Gliclazide
RxNorm normalized name: gliclazide
DrugBank: Gliclazide (DB01120)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gliclazide (60-120 mg)
Trial: NCT00770146
Drug: Mipomersen sodium
RxNorm normalized name: Mipomersen Sodium
DrugBank: Mipomersen (DB05528)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 200 mg/mL
Trial: NCT00003798
Drug: motexafin gadolinium
RxNorm normalized name: Motexafin gadolinium
DrugBank: Motexafin gadolinium (DB05428)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03413722
Drug: Tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The patient's physician will prescribe drug according to standard practice.
Trial: NCT03413722
Drug: Everolimus
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: The patient's physician will prescribe drug according to standard practice.
Trial: NCT03620201
Drug: Bintrafusp Alfa
RxNorm normalized name: Bintrafusp alfa
DrugBank: Bintrafusp alfa (DB15387)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT03800550
Drug: Bedaquiline
RxNorm normalized name: Bedaquiline
DrugBank: Bedaquiline (DB08903)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Bedaquiline tablet will be administered, orally.
Trial: NCT03203746
Drug: Lycopene + SRP
DrugBank: Lycopene (DB11231)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01864356
Drug: NT100
RxNorm normalized name: POMEGRANATE 250 mg / EUCOMMIA ULMOIDES BARK 200 mg / ACHYRANTHES JAPONICA ROOT 50 mg ORAL TABLET [HL Joint100 for Joint and Cartilage]
DrugBank: Eucommia ulmoides bark (DB14259)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04111978
Drug: Letrozole 2.5mg
RxNorm normalized name: LETROZOLE 2.5MG TAB
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aromatase inhibitor
Trial: NCT02195011
Drug: Regorafenib
RxNorm normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: All patients will take regorafenib 160mg orally once daily on Days 1-21 of each 28-day cycle.
Trial: NCT00674154
Drug: Cholecalciferol
RxNorm normalized name: Cholecalciferol
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2800 IE daily in 52 weeks
Trial: NCT03494816
Drug: Axitinib Oral Tablet
RxNorm normalized name: axitinib Oral Tablet
DrugBank: Axitinib (DB06626)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Axitinib is an oral VEGF-receptor inhibitor. Patients are prescribed a starting dose of 5mg twice daily, escalating to 10mg in absence of dose limiting toxicities and blood pressure.~Doses should be taken approximately 12 hours apart and patients should be instructed to take their doses at approximately the same times each day with or without food as per instruction. On clinic days only, patients will be advised to fast for 6 hours prior to their clinic visit.~Patients should be advised to stop axitinib treatment a minimum of 36 hours and maximum of 7 days prior to week 9 nephrectomy and thrombectomy surgery.~Dose adjustments, including dose increase or dose reduction, are permitted and should be based on clinical judgement and the guidelines provided in the protocol.
Trial: NCT02250833
Drug: CKD-828
RxNorm normalized name: CKD-504
DrugBank: CKD-504 (DB18235)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telmisartan 80mg /S-Amlodipine 5mg(FDC) Tablet, Oral, Once Daily
Trial: NCT02250833
Drug: Telmisartan
RxNorm normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: - Telmisartan 80mg tablet, Oral, Once Daily (Combination Therapy with S-amlodipine)
Trial: NCT02250833
Drug: S-amlodipine
RxNorm normalized name: S-amlodipine
DrugBank: Levamlodipine (DB09237)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: - S-amlodipine 5mg tablet, Oral, Once Daily (combination Therapy with Telmisartan)
Trial: NCT02775240
Drug: Digoxin
RxNorm normalized name: Digoxin
DrugBank: Digoxin (DB00390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.5 mg (2 x 0.25 mg) Digoxin oral dose
Trial: NCT02775240
Drug: Maribavir
RxNorm normalized name: MARIBAVIR
DrugBank: Maribavir (DB06234)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 200mg twice a day for 8 days
Trial: NCT02775240
Drug: Dextromethorphan
RxNorm normalized name: Dextromethorphan
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 30 mg oral dose
Trial: NCT01203852
Drug: Metoprolol
RxNorm normalized name: Metoprolol
DrugBank: Metoprolol (DB00264)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metoprolol 50 mg twice daily titrated to 100 mg twice daily~Note: due to discontinuation of the manufacture of chlorthalidone 15 mg, effective Jan 1, 2013; the starting dose of chlorthalidone will be 25 mg 4 times per week (Mon, Wed, Thur, Sat) with subsequent titration to 25 mg daily.
Trial: NCT02756988
Drug: Coppertone (BAY987704)
DrugBank: Copper (DB09130)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Number: X71-109)
Trial: NCT00600145
Drug: Mirtazapine
RxNorm normalized name: Mirtazapine
DrugBank: Mirtazapine (DB00370)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 15 mg Mirtazapine is administered followed 2 hours later by 20 mg of methamphetamine / placebo (administered at each testing visit)
Trial: NCT01433276
Drug: Hyperosmolar sodium lactate
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1st loading : Upto 2 liters of Ringer's lactate, followed by Totilac which was given 5 mL/kgBW/15 minutes, followed by maintenance 2 mL/kgBW/hour for 3 hours
Trial: NCT01991184
Drug: GDC-0853
RxNorm normalized name: calcium carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Multiple escalating doses
Trial: NCT01613170
Drug: Toviaz
RxNorm normalized name: Toviaz
DrugBank: Fesoterodine (DB06702)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Toviaz 4mg daily
Trial: NCT01613170
Drug: Premarin
RxNorm normalized name: Premarin
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Premarin cream 1 g per vagina twice weekly
Trial: NCT04037683
Drug: Misoprostol Oral Tablet
RxNorm normalized name: misoprostol Oral Tablet
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Misoprostol 25mcg orally given 2-hourly
Trial: NCT04037683
Drug: Oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxytocin infusion
Trial: NCT00199095
Drug: Adriamycin
RxNorm normalized name: Adriamycin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00199095
Drug: Cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00199095
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00199095
Drug: Idarubicin
RxNorm normalized name: Idarubicin
DrugBank: Idarubicin (DB01177)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00199095
Drug: Ifosfamide
RxNorm normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00199095
Drug: VM26
RxNorm normalized name: Teniposide
DrugBank: Teniposide (DB00444)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00199095
Drug: Vincristine
RxNorm normalized name: Vincristine
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01863654
Drug: Montelukast 5 mg chewable tablets
RxNorm normalized name: montelukast
DrugBank: Montelukast (DB00471)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reference product
Trial: NCT01863654
Drug: Montelukast 5 mg chewable tablets
RxNorm normalized name: montelukast
DrugBank: Montelukast (DB00471)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Test product